PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT06710132

Title field or adapter rule

{'original_value': 'PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)', 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-10-31T23:27:22.587397+00:00

Published At

2026-10-22T00:00:00+00:00

Record Updated At

2026-10-22

Source Retrieved At

2026-10-31T22:17:25.750886+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Solid Tumors", "Gastric Cancer", "Non-Small Cell Lung Cancer (NSCLC)", "Pancreatic Cancer", "Pancreatic Ductal Adenocarcinoma (PDAC)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-22", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT06710132"

protocolSection.identificationModule.officialTitle

"PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (Master Protocol)"

protocolSection.statusModule.overallStatus

"ACTIVE_NOT_RECRUITING"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

null

Study condition terms

• Solid Tumors (protocolSection.conditionsModule.conditions)
• Gastric Cancer (protocolSection.conditionsModule.conditions)
• Non-Small Cell Lung Cancer (NSCLC) (protocolSection.conditionsModule.conditions)
• Pancreatic Cancer (protocolSection.conditionsModule.conditions)
• Pancreatic Ductal Adenocarcinoma (PDAC) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Substudy GC: M9140 Monotherapy - Part A CEACAM5 High', 'Substudy GC: M9140 Monotherapy - Part B CEACAM5 Low', 'Substudy NSCLC: M9140 Monotherapy - Part A CEACAM5 High EGFR Wt', 'Substudy NSCLC: M9140 Monotherapy - Part B CEACAM5 High EGFR mut', 'Substudy PDAC: M9140 Monotherapy - Part A CEACAM5 High'], 'description': 'All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.', 'name': 'M9140', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

• M9140 (protocolSection.armsInterventionsModule.interventions[].name)

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.